JP2016040284A5 - - Google Patents

Download PDF

Info

Publication number
JP2016040284A5
JP2016040284A5 JP2015190399A JP2015190399A JP2016040284A5 JP 2016040284 A5 JP2016040284 A5 JP 2016040284A5 JP 2015190399 A JP2015190399 A JP 2015190399A JP 2015190399 A JP2015190399 A JP 2015190399A JP 2016040284 A5 JP2016040284 A5 JP 2016040284A5
Authority
JP
Japan
Prior art keywords
neisseria meningitidis
capsular saccharide
meningitidis serogroup
saccharide conjugate
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015190399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016040284A (ja
JP6250008B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016040284A publication Critical patent/JP2016040284A/ja
Publication of JP2016040284A5 publication Critical patent/JP2016040284A5/ja
Application granted granted Critical
Publication of JP6250008B2 publication Critical patent/JP6250008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015190399A 2012-03-09 2015-09-28 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法 Active JP6250008B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609257P 2012-03-09 2012-03-09
US61/609,257 2012-03-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014560503A Division JP5925342B2 (ja) 2012-03-09 2013-03-06 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法

Publications (3)

Publication Number Publication Date
JP2016040284A JP2016040284A (ja) 2016-03-24
JP2016040284A5 true JP2016040284A5 (OSRAM) 2016-05-12
JP6250008B2 JP6250008B2 (ja) 2017-12-20

Family

ID=48182966

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014560503A Active JP5925342B2 (ja) 2012-03-09 2013-03-06 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
JP2015190399A Active JP6250008B2 (ja) 2012-03-09 2015-09-28 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014560503A Active JP5925342B2 (ja) 2012-03-09 2013-03-06 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法

Country Status (20)

Country Link
US (3) US8986710B2 (OSRAM)
EP (3) EP4043029A1 (OSRAM)
JP (2) JP5925342B2 (OSRAM)
KR (5) KR101784142B1 (OSRAM)
CN (3) CN105693830B (OSRAM)
AR (3) AR090294A1 (OSRAM)
AU (5) AU2013229063B2 (OSRAM)
BR (2) BR122016004924A2 (OSRAM)
CA (4) CA3195971A1 (OSRAM)
CO (1) CO7061042A2 (OSRAM)
IL (4) IL234555B (OSRAM)
MX (3) MX351993B (OSRAM)
MY (2) MY167723A (OSRAM)
NZ (2) NZ718108A (OSRAM)
PE (2) PE20142115A1 (OSRAM)
PH (2) PH12014501887B1 (OSRAM)
RU (2) RU2665841C2 (OSRAM)
SG (3) SG11201404730XA (OSRAM)
TW (5) TWI570133B (OSRAM)
WO (1) WO2013132452A2 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
WO2016014719A1 (en) * 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20180080178A (ko) * 2015-08-11 2018-07-11 오르비스 헬스 솔루션즈 엘엘씨 세균성 백신 및 바이러스성 백신 방법
US20180228885A1 (en) * 2016-03-04 2018-08-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
LT3506935T (lt) 2016-09-02 2024-04-25 Sanofi Pasteur, Inc. Vakcina nuo neisseria meningitidis
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018089942A1 (en) 2016-11-10 2018-05-17 Slipchip Corporation Polynucleotides for the amplification and detection of chlamydia trachomatis
CN118021947A (zh) * 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US12264365B2 (en) 2020-03-23 2025-04-01 Talis Biomedical Corporation Polynucleotides for amplification and detection of SARS-CoV-2
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
KR102706383B1 (ko) 2023-05-18 2024-09-11 지에스칼텍스 주식회사 주유소 배관 설치 구조물

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
WO1989007150A1 (en) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
ES2063965T3 (es) 1989-03-09 1995-01-16 Praxis Biolog Inc Vacunas para haemophilus influenzae no tipificable.
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
AU658836B2 (en) 1990-09-25 1995-05-04 Xenova Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
CA2121493A1 (en) 1991-10-21 1993-04-29 Charles K. Stover Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
ES2145072T3 (es) 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
WO1996039036A1 (en) 1995-06-05 1996-12-12 The University Of Alabama At Birmingham Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
DK0832093T3 (da) 1995-06-07 2007-01-08 Sanofi Pasteur Inc Udtrykkelse af lipoproteiner
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
EP0939647B2 (en) 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
PL337584A1 (en) 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Improved method of transferring nucleic acid to eucariotic cells of multiple-cell organisms and connection enabling accomplishment of this method
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
BR9810500A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Sistema e aparelho para a transferência de ácido nucléico in vivo para o interior de células de organismos eucarióticos pluricelulares
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
EP1007546B1 (en) 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal b epitopes
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
WO1999040200A1 (en) 1998-02-03 1999-08-12 Center For Disease Control And Prevention RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
AU761495B2 (en) 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
DE69919754T2 (de) 1998-09-30 2005-09-01 Walter Reed Army Institute Of Research Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
CN1911959A (zh) * 1998-10-09 2007-02-14 希龙公司 奈瑟球菌基因组序列及其用途
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
CN1350585A (zh) 1999-01-15 2002-05-22 史密丝克莱恩比彻姆生物有限公司 脑膜炎奈瑟氏菌多肽basb052
CA2360658A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
JP4812942B2 (ja) 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN1433471A (zh) 1999-11-29 2003-07-30 启龙股份公司 85kgDa奈瑟球菌的抗原
JP4948731B2 (ja) 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 凍結乾燥の際に生物学的分子を安定化するための組成物および方法
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
DE60144353D1 (de) 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
DK1355673T3 (da) 2001-01-23 2012-09-17 Sanofi Pasteur Inc Multivalent meningococvaccine bestående af et polysaccharid/proteinkonjugat
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2441327A1 (en) 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
WO2002083710A2 (en) 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
BR0210216A (pt) 2001-06-07 2004-06-08 Wyeth Corp Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003025132A2 (en) 2001-09-14 2003-03-27 Invitrogen Corporation Dna polymerases and mutants thereof
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
CA2480389C (en) 2002-03-26 2012-10-09 Chiron Srl Modified saccharides having improved stability in water
EP1506007B1 (en) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2006525330A (ja) 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
MXPA05014171A (es) 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1961426B1 (en) 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
JP2007517057A (ja) 2003-12-30 2007-06-28 ワイス 改善された耐容性を有する免疫原性組成物中の疎水性タンパク質の処方物
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006011060A2 (en) 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
CA2600113A1 (en) 2005-03-07 2006-09-14 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biological S North America Pharmaceutical liposomal compositions
AU2006245440B2 (en) 2005-05-06 2012-04-19 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-A vaccines
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
ATE485516T1 (de) 2005-09-05 2010-11-15 Glaxosmithkline Biolog Sa Bakterizidie-serumtest für n. meningitidis spezifische antiseren
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
KR20080079697A (ko) 2005-12-23 2008-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 컨쥬게이트 백신
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
AU2007263531B2 (en) 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
HUE048973T2 (hu) 2006-07-27 2020-09-28 Wyeth Llc Nagy sejtsûrûségû, rátáplálásos-szakaszos fermentáló eljárás rekombináns fehérje elõállítására
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
IN2009KN04098A (OSRAM) 2007-06-04 2015-08-28 Novartis Ag
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CA2695467A1 (en) 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
RU2475496C2 (ru) * 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
WO2009143168A2 (en) 2008-05-19 2009-11-26 Novartis Ag Vaccine assays
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
BRPI0917306A2 (pt) 2008-08-27 2016-04-19 Childrens Hosp & Res Ct Oak ensaios com base fator de complemento h para a atividade sérica bacterecida contra neisseria meningitidis
CA2733943A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010242905B2 (en) * 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012022669A2 (pt) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
RU2665841C2 (ru) * 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
JP2016519160A (ja) * 2013-05-22 2016-06-30 パール セラピューティクス，インコーポレイテッド ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
BR112016004463A2 (pt) * 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas

Similar Documents

Publication Publication Date Title
JP2016040284A5 (OSRAM)
PH12018501517B1 (en) Neisseria meningitidis compositions and methods thereof
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2009039854A8 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
PH12018500037A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12013500453B1 (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
JP2015214545A5 (OSRAM)
HRP20231504T1 (hr) Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
WO2014136064A3 (en) Immunogenic fusion polypeptides
JP2010011868A5 (OSRAM)
JP2013502918A5 (OSRAM)
JP2017523985A5 (OSRAM)
WO2014007982A3 (en) C-terminal and central epitope a-beta antibodies
JP2016106117A5 (OSRAM)
JP2012524099A5 (OSRAM)
JP2015529677A5 (OSRAM)
MA45283B1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
JP2016531853A5 (OSRAM)
WO2013066731A3 (en) Protective vaccine based on staphylococcus aureus sa2451 protein